This article is from the source 'independent' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at http://www.independent.co.uk/news/uk/medipen-cbd-vaporiser-uk-gets-first-publicly-available-dedicated-cannabis-weed-marijuana-research-a7789891.html
The article has changed 4 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| UK gets first publicly available dedicated cannabis research facility | UK gets first publicly available dedicated cannabis research facility |
| (35 minutes later) | |
| Cannabinoid biotechnology company MediPen Ltd. is launching its own dedicated 1,800ft sq marijuana research facility this summer, which will also provide a platform for anyone looking to utilise its facilities for the purposes of driving innovation around the use of medicinal cannabis. | Cannabinoid biotechnology company MediPen Ltd. is launching its own dedicated 1,800ft sq marijuana research facility this summer, which will also provide a platform for anyone looking to utilise its facilities for the purposes of driving innovation around the use of medicinal cannabis. |
| The company, which has had big success selling non-psychoactive CBD vaporisers that users claim to have a long list of medicinal benefits, is currently in the process of securing a license from the Home Office to import and work with controlled compounds found in cannabis so it can study the plant in greater detail. | |
| These include Δ9-Tetrahydrocannabinol (THC), which will be studied in the laboratory with regard to cancer patients and with the aim of minimising the negative impact of existing chemotherapy-based treatments such as nausea and vomiting through its antiemetic properties, along with attempting to suppress metastasis through inhibiting the proliferation of cancer cells. | These include Δ9-Tetrahydrocannabinol (THC), which will be studied in the laboratory with regard to cancer patients and with the aim of minimising the negative impact of existing chemotherapy-based treatments such as nausea and vomiting through its antiemetic properties, along with attempting to suppress metastasis through inhibiting the proliferation of cancer cells. |
| Last summer, MediPen devices were tested by an NHS unit, an unprecedented step that helped increased scrutiny on cannabis’ medical benefits. | Last summer, MediPen devices were tested by an NHS unit, an unprecedented step that helped increased scrutiny on cannabis’ medical benefits. |
| "As it stands there is a significant amount of scientific data available detailing the powerful effects of cannabinoids within cell culture systems and in vivo," a representative told The Independent. "However, we plan to be amongst the first in the world to begin clinical trials on humans." | "As it stands there is a significant amount of scientific data available detailing the powerful effects of cannabinoids within cell culture systems and in vivo," a representative told The Independent. "However, we plan to be amongst the first in the world to begin clinical trials on humans." |
| GW Pharmaceuticals is also developing cannabinoid based medicine from its own facility, but MediPen's will be a little different in its public availability, allowing use of its facilities to founders of other cannabis based innovations who are encouraged to take advantage of their established R&D network, state of the art in-house testing as well as on board business and legal advice. | GW Pharmaceuticals is also developing cannabinoid based medicine from its own facility, but MediPen's will be a little different in its public availability, allowing use of its facilities to founders of other cannabis based innovations who are encouraged to take advantage of their established R&D network, state of the art in-house testing as well as on board business and legal advice. |